Design Therapeutics, Inc.

For the period ended Sep 30, 2026. Filed Nov 4, 2026.

About this filing

A company's report for each of its first three quarters. The financial statements are not audited. It shows how the business has moved since the last annual report, and what management says changed.

Sep 30, 2026 · Filed Nov 4, 2026

DSGN$10.21+5.6%Stored close · as of Nov 6, 2026

Extracted filing text, with the paragraph anchors used by the comparison.

See the whole filing, with its images and exhibits

Condensed Balance Sheets

(in thousands, except share and par value data)

	September 30,	December 31,
	2026	2025
(unaudited)
Assets
Current assets:
Cash and cash equivalents	$15,252	$16,856
Investment securities	193,356	202,989
Prepaid expenses and other current assets	5,355	3,939
Total current assets	213,963	223,784
Property and equipment, net	573	981
Right-of-use asset	2,272	1,438
Total assets	$216,808	$226,203
Liabilities and Stockholders’ Equity
Current liabilities:
Accounts payable	$2,078	$2,312
Accrued expenses and other current liabilities (including related party amounts of $890 as of December 31, 2025)	10,675	10,743
Total current liabilities	12,753	13,055
Operating lease liability	1,859	645
Total liabilities	14,612	13,700
Commitments and contingencies (See Note 8)
Stockholders’ equity:
Common stock, $0.0001 par value; 200,000,000 shares authorized at September 30, 2026 and December 31, 2025; 63,785,058 and 60,398,051 shares issued and outstanding at September 30, 2026 and December 31, 2025, respectively	6	6
Additional paid-in capital	558,967	509,100
Accumulated deficit	(355,095)	(297,006)
Accumulated other comprehensive (loss) income	(1,682)	403
Total stockholders’ equity	202,196	212,503
Total liabilities and stockholders’ equity	$216,808	$226,203

ContentsView on SEC.gov

The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.